Business Context and Reporting Period
This Form 8-K Current Report was filed by Trovagene, Inc. on October 30, 2013. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the appointment of Dr. Paul Billings as a member of the Board of Directors, effective October 30, 2013. Dr. Billings brings extensive experience in genomics and molecular medicine, including roles as Chief Medical Officer at Life Technologies and service on the FDA Scientific Advisory Board.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. The document serves solely to disclose the board appointment and includes a press release as Exhibit 99.1.
Investor Verification Checklist
- Verify the correct registrant name (Trovagene, Inc. vs. Cardiff Oncology, Inc.) to ensure data alignment.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Billings' strategic value.
- Consult the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.